SMT202100575T1 - Nuova forma polimorfa di n-[2-(6-fluoro-1h-indol-3-il)etil]-3-(2,2,3,3-tetrafluoropro-possi)benzilammina cloridrato - Google Patents

Nuova forma polimorfa di n-[2-(6-fluoro-1h-indol-3-il)etil]-3-(2,2,3,3-tetrafluoropro-possi)benzilammina cloridrato

Info

Publication number
SMT202100575T1
SMT202100575T1 SM20210575T SMT202100575T SMT202100575T1 SM T202100575 T1 SMT202100575 T1 SM T202100575T1 SM 20210575 T SM20210575 T SM 20210575T SM T202100575 T SMT202100575 T SM T202100575T SM T202100575 T1 SMT202100575 T1 SM T202100575T1
Authority
SM
San Marino
Prior art keywords
tetrafluoropropoxy
indol
alzheimer
fluoro
ethyl
Prior art date
Application number
SM20210575T
Other languages
English (en)
Inventor
Michael Harold Rock
Diego Heidi Lopez De
Kristine Birklund Andersen
Frans Dennis Therkelsen
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58794010&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SMT202100575(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by H Lundbeck As filed Critical H Lundbeck As
Publication of SMT202100575T1 publication Critical patent/SMT202100575T1/it

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
SM20210575T 2014-07-04 2015-07-03 Nuova forma polimorfa di n-[2-(6-fluoro-1h-indol-3-il)etil]-3-(2,2,3,3-tetrafluoropro-possi)benzilammina cloridrato SMT202100575T1 (it)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA201400369 2014-07-04
EP15733469.9A EP3164385B1 (en) 2014-07-04 2015-07-03 Novel polymorphic form of n-[2-(6-fluoro-lh-indol-3-yl)ethyl]-3-(2,2,3,3-tetrafluoropropoxy)benzylamine hydrochloride for the treatment of alzheimer's
PCT/EP2015/065176 WO2016001398A1 (en) 2014-07-04 2015-07-03 Novel polymorphic form of n-[2-(6-fluoro-lh-indol-3-yl)ethyl]-3-(2,2,3,3-tetrafluoropropoxy)benzylamine hydrochloride for the treatment of alzheimer's

Publications (1)

Publication Number Publication Date
SMT202100575T1 true SMT202100575T1 (it) 2021-11-12

Family

ID=58794010

Family Applications (1)

Application Number Title Priority Date Filing Date
SM20210575T SMT202100575T1 (it) 2014-07-04 2015-07-03 Nuova forma polimorfa di n-[2-(6-fluoro-1h-indol-3-il)etil]-3-(2,2,3,3-tetrafluoropro-possi)benzilammina cloridrato

Country Status (42)

Country Link
US (1) US10071963B2 (it)
EP (1) EP3164385B1 (it)
JP (2) JP6643330B2 (it)
KR (1) KR102399374B1 (it)
CN (3) CN112961094A (it)
AP (1) AP2016009643A0 (it)
AR (1) AR101109A1 (it)
AU (1) AU2015282909B2 (it)
CA (1) CA2951794C (it)
CL (1) CL2017000002A1 (it)
CO (1) CO2017000019A2 (it)
CR (1) CR20160605A (it)
CY (1) CY1124594T1 (it)
DK (1) DK3164385T3 (it)
DO (1) DOP2017000001A (it)
EA (1) EA035894B1 (it)
EC (1) ECSP17000222A (it)
ES (1) ES2893619T3 (it)
GE (2) GEAP202114363A (it)
HR (1) HRP20211596T8 (it)
HU (1) HUE056368T2 (it)
IL (1) IL249428B (it)
JO (1) JO3639B1 (it)
LT (1) LT3164385T (it)
MA (1) MA40345B1 (it)
MX (1) MX377013B (it)
MY (1) MY190715A (it)
NZ (1) NZ727251A (it)
PE (1) PE20170522A1 (it)
PH (1) PH12016502477A1 (it)
PL (1) PL3164385T3 (it)
PT (1) PT3164385T (it)
RS (1) RS62380B1 (it)
RU (1) RU2016151637A (it)
SG (1) SG11201610334XA (it)
SI (1) SI3164385T1 (it)
SM (1) SMT202100575T1 (it)
SV (1) SV2016005353A (it)
TN (1) TN2016000549A1 (it)
TW (1) TWI665188B (it)
UA (1) UA121547C2 (it)
WO (1) WO2016001398A1 (it)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3333154A1 (en) 2016-12-07 2018-06-13 Sandoz Ag Crystalline form of a selective 5-ht6 receptor antagonist

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1859798T3 (en) 2001-03-29 2016-03-21 Lilly Co Eli N- (2-arylethyl) -BENZYLAMINER as antagonists of 5-HT6 receptor
TW201139370A (en) * 2009-12-23 2011-11-16 Lundbeck & Co As H Processes for the manufacture of a pharmaceutically active agent
JO3459B1 (ar) * 2012-09-09 2020-07-05 H Lundbeck As تركيبات صيدلانية لعلاج مرض الزهايمر
CN105175307A (zh) 2014-11-18 2015-12-23 苏州晶云药物科技有限公司 Lu AE58054的盐酸盐晶型A及其制备方法和用途

Also Published As

Publication number Publication date
PE20170522A1 (es) 2017-05-28
EA035894B1 (ru) 2020-08-27
CO2017000019A2 (es) 2017-05-31
EP3164385A1 (en) 2017-05-10
HUE056368T2 (hu) 2022-02-28
GEP20227368B (en) 2022-03-25
BR112017000127A2 (pt) 2018-01-23
AP2016009643A0 (en) 2016-12-31
RU2016151637A (ru) 2018-08-08
GEAP202114363A (en) 2021-12-10
TW201625525A (zh) 2016-07-16
MA40345B1 (fr) 2021-10-29
IL249428B (en) 2019-10-31
MX2016016895A (es) 2017-04-27
CN112961094A (zh) 2021-06-15
US20170152227A1 (en) 2017-06-01
CL2017000002A1 (es) 2017-06-23
NZ727251A (en) 2023-06-30
UA121547C2 (uk) 2020-06-25
EA201692485A1 (ru) 2017-05-31
HRP20211596T1 (hr) 2022-01-07
AU2015282909A1 (en) 2017-01-05
CR20160605A (es) 2017-04-24
DK3164385T3 (da) 2021-10-11
MA40345A (fr) 2021-04-28
KR20170023019A (ko) 2017-03-02
PT3164385T (pt) 2021-10-07
PH12016502477B1 (en) 2017-04-10
MY190715A (en) 2022-05-12
JP2017519829A (ja) 2017-07-20
JP2020059724A (ja) 2020-04-16
US10071963B2 (en) 2018-09-11
KR102399374B1 (ko) 2022-05-17
AR101109A1 (es) 2016-11-23
ECSP17000222A (es) 2017-02-24
ES2893619T3 (es) 2022-02-09
PH12016502477A1 (en) 2017-04-10
CA2951794A1 (en) 2016-01-07
CN112961095A (zh) 2021-06-15
SV2016005353A (es) 2017-03-23
DOP2017000001A (es) 2017-03-31
CY1124594T1 (el) 2022-07-22
JP6643330B2 (ja) 2020-02-12
HRP20211596T8 (hr) 2022-03-04
EP3164385B1 (en) 2021-09-08
CN106458889A (zh) 2017-02-22
SG11201610334XA (en) 2017-01-27
AU2015282909B2 (en) 2019-02-07
CA2951794C (en) 2023-03-07
RU2016151637A3 (it) 2019-01-28
PL3164385T3 (pl) 2021-12-20
RS62380B1 (sr) 2021-10-29
MX377013B (es) 2025-03-07
TN2016000549A1 (en) 2018-04-04
TWI665188B (zh) 2019-07-11
SI3164385T1 (sl) 2021-10-29
JO3639B1 (ar) 2020-08-27
IL249428A0 (en) 2017-02-28
WO2016001398A1 (en) 2016-01-07
LT3164385T (lt) 2021-10-11

Similar Documents

Publication Publication Date Title
SI3097098T1 (sl) Postopek za pripravo N-((3-aminooksetana-3-il)metil)-2-(1,1-diokso- 3,5-dihidro-1,4-benzotiazepin-4-il)-6-metil-kinazolin-4-amina
IL246875A0 (en) 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahydropyridines as bace1 inhibitors for the treatment of Alzheimer's disease
IL252433B (en) Methods for treating Alzheimer's disease
IL247085A0 (en) Methods for treating Alzheimer's disease
IL246999A0 (en) Methods for treating Alzheimer's disease
PL3285755T3 (pl) Chlorowodorek kreatyny do leczenia choroby Huntingtona
LT3413870T (lt) Igmesinas, skirtas panaudoti alzheimerio ligos gydymui
IL249428A0 (en) A polymorphic form of n-[2-(6 fluoro-lh-indol-3-yl)ethyl]-3-(2, 2, 3, 3-tetrafluoropropoxy)benzylamine hydrochloride for the treatment of Alzheimer's
PL3153022T3 (pl) N-(3’,4’-dichloro-5-metoksybifenyl-2-ylo)-3-(difluorometylo)-1-metylo-1H-pirazolo-4-karboksyamid
ZA201603729B (en) Process for the preparation of n-[(3-aminooxetan-3-yl)methyl]-2-(1,1-dioxo-3,5-dihydro-1,4-benzothiazepin-4-yl)-6-methyl-quinazolin-4-amine
GB201511453D0 (en) Treatment of alzheimer's disease